Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells.
Vinod GanjuGavin MarxScott PattisonNancy B Amaro-MugridgeJing-Ting ZhaoBryan R G WilliamsJennifer A MacDiarmidHimanshu BrahmbhattPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
E-EDV-D682/GC provided significant OS, minimal side effects and weight stabilization in advanced PDAC patients. Advanced PDAC can be safely treated with super-cytotoxic drugs via EDVs to overcome multi-drug resistance.
Keyphrases
- newly diagnosed
- end stage renal disease
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- study protocol
- body mass index
- physical activity
- peritoneal dialysis
- tyrosine kinase
- randomized controlled trial
- cancer therapy
- phase iii
- drug induced
- patient reported outcomes
- weight gain
- drug delivery
- high resolution
- liquid chromatography
- anti inflammatory